Lung Cancer
Expression analysis of long non-coding RNAs GSTT1-AS1 and IFNG-AS1 and their target genes in lung cancer
Authors: Farbod Esfandi, Zabih Mir Hassani, Shahram Arsang-Jang, Mohammad Taheri, Soudeh Ghafouri-Fard
Long non-coding RNAs (lncRNAs) have recently gained attention because of their regulatory roles on expression of genes involved in the immune response and cancer. In the present study, we evaluated expression of two lncRNAs (GSTT1-AS1 and IFNG-AS1) and their target genes (TNFA and IFNG) in human lung cancer samples and their adjacent non-cancerous tissues.. Read More»
- Genet. Mol. Res. 18(3):
Role of KRAS in NSCLC: present and future
Authors: Addeo A, Bini R
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite therapeutic advances over the last several decades, the overall 5-year survival remains only 16%. (Siegel R, 2013). Molecular studies have indicated that Adenocarcinomas have distinct genomic alterations allowing classification into clinically relevan.. Read More»
- Genet. Mol. Res. 17(1):
- gmr16039873
- DOI:
- 10.4238/gmr16039873
ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy
Authors: H. Zhang1, J. Li2, Y. Zhang2, M. Sun3, P. Zhao1, G. Zhang2, C. Jin2, L. Sun1, M. He1, B. Wang2 and X. Zhang2
We conducted a prospective study to analyze the expression of the excision repair cross-complementing group 1 (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) genes in 297 Chinese patients with advanced non-small cell lung cancer (NSCLC). The goal of this study was to evaluate these genes as potential biomarkers for prediction of tumor response and .. Read More»
- Genet. Mol. Res. 13(4):
- 2014.December.4.16
- DOI:
- 10.4238/2014.December.4.16
ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy
Authors: H. Zhang1, J. Li2, Y. Zhang2, M. Sun3, P. Zhao1, G. Zhang2, C. Jin2, L. Sun1, M. He1, B. Wang2 and X. Zhang2
We conducted a prospective study to analyze the expression of the excision repair cross-complementing group 1 (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) genes in 297 Chinese patients with advanced non-small cell lung cancer (NSCLC). The goal of this study was to evaluate these genes as potential biomarkers for prediction of tumor response and .. Read More»
- Genet. Mol. Res. 13(4):
- 2014.December.4.16
- DOI:
- 10.4238/2014.December.4.16
Association between the -77T>C polymorphism in the DNA repair gene XRCC1 and lung cancer risk
Authors: B.B. Sun, J.Z. Wu, Y.G. Li and L.J. Ma
Numerous studies have evaluated the association between the X-ray repair cross-complementing group 1 (XRCC1) DNA repair gene polymorphism -77T>C and lung cancer risk. However, this association is controversial. We used PubMed and Embase to identify 5 case-control studies, which included 2488 lung cancer cases and 2576 controls, for inclusion in a compr.. Read More»
- Genet. Mol. Res. 13(4):
- 2014.December.4.17
- DOI:
- 10.4238/2014.December.4.17
Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine
Authors: M. Zhou, Y.J. Ding, Y. Feng, Q.R. Zhang, Y. Xiang and H.Y. Wan
Xeroderma pigmentosum group D (XPD) plays a key role in the repair of DNA and platinum resistance lesions. Cytidine deaminase (CDA) genes determine the velocity of gemcitabine catalysis. This study aimed to investigate the relationship between XPD and CDA genotypes and outcome in non-small lung cancer (NSCLC) patients. We used.. Read More»
- Genet. Mol. Res. 13(2):
- 2014.April.29.9
- DOI:
- 10.4238/2014.April.29.9
Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer
Authors: D. Liu, J. Wu, G.Y. Shi, H.F. Zhou and Y. Yu
We aimed to assess the role of polymorphisms of the XRCC1 Arg194Trp, XRCC1 Arg399Gln, ERCC5 His1104Asp, and ERCC5 His46His genes on clinical outcomes of advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy regimens. A total of 378 NSCLC patients were asked to participate within 1 month aft.. Read More»
- Genet. Mol. Res. 13(2):
- 2014.April.17.6
- DOI:
- 10.4238/2014.April.17.6
Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy
Authors: T.B. Wang, N.L. Zhang, S.H. Wang, H.Y. Li, S.W. Chen and Y.G. Zheng
We examined mRNA expression levels of ERCC1, BRCA1, RRM1, and human β-tubulin-III (TUBB3) in non-small-cell lung carcinoma (NSCLC) patients and investigated the association between expression of these genes and the clinical outcome of NSCLC treatment. A total of 366 patients who underwent surgery for NSCLC were included i.. Read More»
- Genet. Mol. Res. 13(2):
- http://dx.doi.org/2014.May.9.15
- DOI:
- http://dx.doi.org/10.4238/2014.May.9.15
Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis
Authors: L. Li, C. Wan and F.Q. Wen
X-ray repair cross complementing group 1(XRCC1) polymorphisms have been implicated in interindividual variability of efficacy of platinum chemotherapy for treating non-small cell lung cancer (NSCLC); however, results of different studies have been inconsistent. We conducted a meta-analysis to investigate the association betwee.. Read More»
- Genet. Mol. Res. 13(2):
- http://dx.doi.org/2014.May.16.1
- DOI:
- http://dx.doi.org/10.4238/2014.May.16.1
Azithromycin enhances the favorable results of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer
Authors: D.J. Chu, D.E. Yao, Y.F. Zhuang, Y. Hong, X.C. Zhu, Z.R. Fang, J. Yu and Z.Y. Yu
Although new chemotherapeutic drugs have been applied constantly, their efficacy for non-small cell lung cancer (NSCLC) is still not satisfactory. In recent years, epidemiological investigations have shown that lung cancer may be induced by chronic Chlamydia pneumoniae (Cpn) infection, since stable high titers of Cpn antibodie.. Read More»
- Genet. Mol. Res. 13(2):
- 2014.April.14.8
- DOI:
- 10.4238/2014.April.14.8